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Summary 
 
 
Human Papillomavirus life cycle requires extensive manipulation of cell signaling to 
provide conditions adequate for viral replication within stratified epithelia. In this 
regard, we show that the E2 regulatory protein of α, β and µ-HPV genotypes 30 
enhances TNF-induced activation of NFκB. This activation is mediated by the N-
terminal domain of E2, but does not rely on its transcriptional properties. It is 
independent of the NFκB regulator Tax1BP1, which nevertheless interacts with all 
the E2 proteins. E2 specifically activates NFκB pathways induced by TNF, while IL1-
induced pathways are not affected. E2 stimulates the activating K63-linked 
ubiquitination of TRAF5, and interacts with both TRAF5 and TRAF6. Our data 
suggest that E2 potentiates TNF-induced NFκB signaling mediated by TRAF5 
activation through direct binding. Since NFκB controls epithelial differentiation, this 
activity may be involved in commitment of infected keratinocytes to proliferation 
arrest and differentiation, both required for implementation of the productive viral 40 
cycle. 
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Main Text       
 
 Human papillomavirus (HPV) infect squamous epithelia of the skin (cutaneous 
HPV) or mucosa of the genital or oral tractus (mucosal HPV). They are responsible 
for asymptomatic infections or induce benign proliferative lesions which possibly 60 
evolve toward malignant progression only for ʻʼhigh riskʼʼ HPV (HR-HPV). 
 Infection initiates in the basal proliferative cells where the E6 and E7 early 
proteins interfere with cell cycle controls, thereby inducing cell proliferation in supra-
basal layers. High levels of viral DNA replication, synthesis of capsid proteins, and 
virus particles assembly are confined to suprabasal and terminally differentiated 
keratinocytes (Doorbar, 2006). The early protein E2 binds to specific sites within the 
viral genome  to ensure its mitotic segregation in basal infected cells, as well as the 
regulation of viral transcription and replication (Desaintes & Demeret, 1996; McBride 
et al., 2006). In addition, the E2 proteins of mucosal HR-HPV directly impact on cell 
proliferation by inducing a G2/M arrest (Bellanger et al., 2005) and apoptosis (Thierry 70 
& Demeret, 2008).  
 Upon viral infection, the host initiates a cell response mediated by NFκB. This 
transcription factor leads to the expression of a large panel of cytokines as well as 
cell cycle and survival genes. Accordingly, many viral pathogens developed 
strategies to modulate NFκB signaling in order to enhance viral replication,  host cell 
survival, and evasion to immune responses (Hiscott et al., 2001). Surprisingly, little is 
known about the regulation of NFκB by HPV. Viral oncoproteins have been reported 
to induce either attenuation or enhancement of NFκB signaling depending on cellular 
context (James et al., 2006; Nair et al., 2003; Nees et al., 2001; Spitkovsky et al., 
2002), and a clear picture of the role of NFκB in the natural history of HPV infection 80 
and HR-HPV associated carcinogenic progression is lacking.  
 To address this issue, we analyzed the impact on NFκB signaling of the 
regulatory E2 proteins from cutaneous HPV of α (HPV 3), β (HPV 5, 8, 9) or  µ (HPV 
1) types, and mucosal α types Low-Risk (LR-HPV 6, 11) or HR (HPV16, 18, 33, 39). 
NFκB activation was monitored through the activity of a luciferase reporter gene 
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under the control of NFκB in HaCaT keratinocytes, with an RNA polIII-directed 
Renilla reporter used as internal control. NFκB activity was measured either without 
or with TNF treatment (20 ng/ml) for 20 hours, as it plays a central role in response to 
viral infection. The E2 proteins were expressed as GFP-fusion proteins which have 
been shown to keep functions, stability and sub-cellular distribution of the untagged 90 
E2 polypeptides (Bellanger et al., 2001; Blachon et al., 2005). All GFP-E2 proteins 
enhanced TNF-induced NFκB activation, when compared to control GFP-expressing 
cells (Figure 1-a). Of note, the E2 proteins from cutaneous β or µ-HPV (HPV1, 5, 8, 
9) activated NFκB reporter to the highest levels. In contrast, E2 proteins had no 
significant effect on NFκB reporter activity without TNF, indicating that E2 did not 
induce constitutive NFκB signaling (supplemental Figure 1). 
 The untagged version of E2 from HPV 5, 11 and 18 enhanced TNF-induced 
activation of the NFκB reporter similarly as their  GFP fusion counterparts, indicating 
that the GFP tag does not exaggerate the observed NFκB activation (Figure 1-b, left 
panel). The expression of untagged E2 proteins was monitored through activation a 100 
synthetic E2-responsive promoter (Thierry et al., 1990) (Figure 1-b, right panel). 
Overall, these results establish that the E2 proteins of various HPV potentiate TNF-
induced NFκB activation. 
 We next determined whether NFκB activation could be assigned to a specific 
domain of the E2 protein. The N-terminal domain, central Hinge and C-terminal 
domains of HPV5, 11 and 18 E2 proteins were expressed separately in fusion with 
GFP, and their effect on the activation of NFκB reporter was analyzed. For the three 
E2 proteins, expression of the N-terminal domain enhanced TNF-induced NFκB 
activation, whereas the Hinge and C-terminal domains had no effect (Figure 1-c). The 
transactivation-dead point mutant I77A of HPV 18 E2 (Desaintes et al., 1999) 110 
enhanced TNF-induced NFκB activation with an efficiency similar to that of the wild-
type protein, indicating that N-terminal domain of E2 mediates NFκB activation 
independently of its transcriptional activity (Figure1-d). 
 The E2 proteins from HPV16 and 18 have been shown to interact with 
Tax1BP1 (Wang et al., 2009b), which is a known regulator of NFκB signaling (Journo 
et al., 2009). Despite this interaction could be detected with the whole range of E2 
proteins (see below), silencing of Tax1BP1 through Si-RNA did not relieve HPV5 or 
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18 E2-mediated NFκB activation (Figure 2-a). Tax1BP1-directed Si-RNA reduced the 
level of ectopically expressed Tax1BP1 (Figure 2-b), and lowered E2-dependent 
transcription for HPV16 or 18 E2, but not for HPV5 E2 (supplemental figure 2). 120 
Altogether, these results suggest that enhancement of TNF-induced NFκB activation 
by E2 in HaCaT keratinocytes is not mediated by E2 binding to endogenous 
Tax1BP1. However this interaction affects transcriptional activation by some of the 
E2 proteins, as previously described for BPV1E2 (Wang et al., 2009b).  
 We then analyzed whether E2 could stimulate other NFκB signaling pathways, 
as those triggered by IL1ß. Expression of E2 had no effect on NFκB activation upon 
IL1ß treatment (20 ng/ml for 20 hours), in contrast to TNF-induced NFκB activation 
(Figure 2-c). Our results suggest that the E2 protein specifically activates TNF-
induced NFκB signaling. 
 NFκB signaling involves different intermediates, such as TRAF6 for IL1-130 
induced pathways and TRAF2 or TRAF5 for TNF-induced pathways (Lomaga et al., 
1999; Tada et al., 2001).The TRAF proteins are E3 ubiquitin ligases catalyzing the 
non-degradative K63-linked polyubiquitination of NFκB signaling factors, which plays 
crucial role to recruit and activate downstream factors (Chen & Sun, 2009). We 
examined TRAF ubiquitination patterns in the presence or absence of HPV18 E2 
using HA-tagged ubiquitin with only one lysine available for polyubiquitin chain 
formation at position 29 (K29 ubiquitin), 48 (K48 ubiquitin) or 63 (K63 ubiquitin). As 
shown in Figure 3-a, the polyubiquitination of TRAF5 and 6 was enhanced upon 
HPV18 E2 coexpression, whereas changes were minimal for TRAF2. The activating 
K63-linked ubiquitination of TRAF6 was detected in the absence of E2, in accordance 140 
to previous report (Lamothe et al., 2007). It was not further increased upon E2 
expression, in line with the lack of activation of TRAF6-dependent NFκB pathways by 
E2. In the presence of E2, TRAF6 exhibited enhanced K29- and K48- poly-
ubiquitination, which essentially target proteins for degradation (Xu et al., 2009). In 
contrast, for TRAF5, E2 expression enhanced the activating K63-polyubiquitination, 
concurrently to K29-polyubiquitination (Figure 3), suggesting that E2 enhanced 
TRAF5 activation.  
 We next examined whether E2 could act through direct binding to the TRAF 
proteins, using the SPICA assay (Sensing of Protein-protein Interactions by 
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Complementation Assay). This assay is based on the reconstitution of Gaussia 150 
princeps luciferase activity upon coexpression of interacting proteins in fusion with 
two inactive fragments of the enzyme (Cassonnet et al.) Briefly, reconstituted 
Gaussia activity is expressed as a Ratio of Luminescence, RL. RL is given by the 
Gaussia luciferase activity obtained upon coexpression of protein pairs divided by the 
sum of luciferase activity of each single protein expressed against the corresponding 
empty vector. Using this assay, the binding to Tax1BP1 was detected with all E2 
proteins. In addition, the E2 proteins were found to interact with both TRAF5 and 
TRAF6, but not with TRAF2 (figure 3-b). Such binding potentially underlies the effect 
of E2 on the ubiquitination pattern of TRAF 5 and 6. Altogether, our findings suggest 
that E2 potentiates a TNF-induced NFκB signaling pathway mediated by TRAF5  160 
through direct interaction. 
  In this study, we present evidence that the HPV E2 protein stimulates NFκB 
activity upon TNF induction, through its N terminal domain but independently of its 
transcriptional functions. The E2 protein functions primarily as a regulator of viral 
genome transcription, replication and segregation though binding to the viral genome. 
Our study indicates that E2 activates the transcription of NFκB target genes upon 
TNF induction independently of its transcriptional functions. In addition, this activity is 
independent of the Tax1BP1 protein, although this factor is involved in the regulation 
of NFkB signaling (Journo et al., 2009; Shembade et al., 2007) and binds to E2 
(Wang et al., 2009b) and this study). This interaction has been shown to take part to 170 
the transcriptional activation properties of BPV1 E2 (Wang et al., 2009b), which was 
observed here for HPV16 and 18 E2 proteins. 
 NFκB activation is conserved throughout 11 HPV genotypes representative of 
diverse HPV tropism and pathogenicity, indicating that it is a basic process of HPV 
infection.  The activation of NFκB by TNF has a unique role in the control of epithelial 
differentiation. TNF induces both an arrest in cell proliferation and the activation of 
keratinocyte differentiation markers (Basile et al., 2003; Basile et al., 2001), thereby 
being an essential factor inducing epithelial differentiation. In the course of viral cycle, 
the sensitization to TNF-induced NFκB activation by E2 may be required to activate 
the differentiation program of infected keratinocyte, which is necessary for the late 180 
phase of the viral cycle. The E2 protein is known to alter the transcription of 
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differentiation markers through cooperation with cellular transcription factors as 
C/EBP (Hadaschik et al., 2003)  or through direct binding to cellular promoter (Oldak 
et al., 2004). Our study indicates that E2 possibly stimulates keratinocyte 
differentiation through activation of NFκB target genes. During viral cycle, E6 and E7 
expression prevent cell cycle exit and differentiation of infected keratinocytes. The E2 
protein would overcome these effects by inducing the transcription of keratinocyte 
differentiation genes through multiple mechanisms, including sensitization to TNF-
induced NFκB activation.  
 Since TNF induces a cell cycle arrest in keratinocytes, E2 activity would also 190 
provide adequate conditions for high levels of viral DNA replication, which has been 
shown to occur in pseudo G2-arrested cells in the supra-basal layer of infected 
epithelia (Wang et al., 2009a). Of note, the ß and µ-skin genotypes produce lesions 
with high virus content when compared to lesions associated with α genital HPV. The 
high level of NFκB activation by E2 of cutaneous HPV would thus correlate with viral 
yield, in line with its role in viral DNA replication 
 Several lines of evidence point to a role of E2 in the carcinogenic conversion 
associated with HR-HPV. In case of HR-mucosal HPV, E2 induces a G2/M arrest 
through inactivation of the Anaphase Promoting Complex (Bellanger et al., 2005), 
inducing genomic instability, thus favoring cell immortalization. In addition, E2 from 200 
HR cutaneous HPV8 exhibits intrinsic oncogenic potential when expressed in the skin 
of transgenic mice (Pfefferle et al., 2008). E2-induced skin-tumors are associated to 
impaired wound-healing and chronic inflammation (Pfefferle et al., 2008). Since NFκB 
signaling is a major mediator of inflammation, sustained activation of NFκB by E2 
could have a role in such chronic inflammation, and thus participate to HPV-
associated carcinogenesis. This could add to E6 and E7 immortalizing properties 
during natural infection .  
The TRAF2, 5 and 6 proteins are essential mediators of NFκB signaling. We found 
that E2 stimulates one or both of the K29- or K48- forms of polyubiquitination of 
TRAF5 and TRAF6 which target proteins to degradation (Xu et al., 2009). E2 210 
concurrently stimulates the activating K63-ubiquitination of TRAF 5,  potentially 
underlying the enhancement of TNF-induced NFkB activation by E2.  In addition, E2 
binds to both TRAF5 and TRAF6, providing evidence that E2 could alter their 
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ubiquitination pattern through direct interaction. It is unclear at present how E2 
stimulates the polyubiquitination of TRAF 5 and 6.  It can be envisioned that E2 
binding to the TRAF proteins could facilitate association with Ubiquitin-Activating 
enzymes or ubiquitin ligases, or could increase accessibility of the target lysines 
through conformational changes. Our data nevertheless suggest that E2 potentiates 
a signaling pathway mediated by TRAF5  through direct interaction.  
 In conclusion, we provide evidence that the E2 regulatory protein of human 220 
papillomaviruses manipulates specific cell signaling, as shown here with the 
activation of a TNF-induced NFκB pathway mediated by TRAF5. This effect is likely 
involved in commitment of infected keratinocytes to arrest in proliferation  and 
differentiation, both required for implementation of the productive viral cycle within 
stratified epithelia. Given that cancers arise from initial precancerous productive 
lesions associated with HR-HPV, such activities are relevant for the carcinogenic 
progression of HR-HPV associated lesions. 
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Figures Legend 
 
Figure 1 : Stimulation of TNF-induced activation of NFκB by HPV E2 
protein.(a) HaCaT cells were transfected with NFκB reporter p-NFκB-Luc, p-polIII-
Ren and the indicated GFP-E2 expressing plasmids. Luciferase activity was 
measured 24 hours post transfection, normalized to Renilla and given in Relative 
Luciferase Activity. (b) HaCaT cells transfected with NFκB- or E2- reporters and 
expression plasmids for the indicated untagged E2 proteins or pCIneo, and 
processed as in a. (c) HaCaT cotransfected with NFκB-reporter and expression 350 
plasmids for GFP fusions with N terminal (N), Hinge (H) or C terminal (C) domains of 
HPV5, 11, or 18 E2 proteins, then treated as in a.  (d) HaCaT cotransfected with 
NFκB or E2 reporters and with expression plasmids for wild-type or I77A HPV18 E2 
protein fused to GFP, then treated as in a. Error bars indicate the standard deviation 
of the mean of 2 (without TNF) to 8 (plus TNF) samples. 
 
Figure 2 : E2-mediated NFκB activation is independent of Tax1BP1 and 
specific to TNF induction. (a) HaCaT were transfected with p-NFκB-Luc reporter, 
p-polIII-Ren, GFP-5 E2, GFP-18 E2 or GFP (control) expression plasmids, together 
with Tax1BP1 Si-RNA or  GAPDH Si-RNA (cont). Luciferase activity was measured 360 
20 hours post transfection ( mean of triplicate samples) (b) HaCaT cells were 
cotransfected with expression plasmid for cherry-Tax1BP1 and GAPDH-directed Si-
RNA (control) or Tax1BP1-directed Si-RNA. Cherry-Tax1BP1 was detected with anti-
DsRed Polyclonal antibody, anti-αtubulin was used to normalize for loading. (c) 
HaCaT cells transfected with p-NFκB-Luc, p-polIII Ren, and GFP (control), GFP-5 E2 
or GFP-18 E2 expression plasmids were treated with TNF-α (20 ng/ml) or IL1 (20 
ng/ml) before Luciferase activity was measured. Fold induction gives the relative 
luciferase activity of treated to untreated samples (means of duplicate samples).  
 
 370 
Figure 3 : The interplay of E2 with TRAF signaling intermediates. (a) 293 T  
cells were transfected with GFP-TRAF2, GFP-TRAF5, or GFP-TRAF6 expression 
plasmids together with HA-Ubiquitin K29, K48 or K63 and mCherry-HPV18 E2 (+) or 
mCherry alone (-). Thirty hours post transfection, cell extracts (Habelhah et al., 2004) 
were subjected to immunoprecipitation (IP) with rabbit anti-GFP antibodies. 
Immunoprecipitates were analyzed by western blots with anti-GFP, followed by anti-
HA antibodies. Anti-GFP and anti-18E2 western blots were performed on cell 
extracts. (b) SPICA experiments were performed in 293 cells. Reconstituted Gaussia 
activity is expressed as a Ratio of Luminescence, RL. The threshold of positive 
interaction has been determined to be 3,5 and is indicated in the figure.  380 
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